Form 8-K - Current report:
SEC Accession No. 0001104659-25-068670
Filing Date
2025-07-17
Accepted
2025-07-17 16:19:27
Documents
13
Period of Report
2025-07-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2521089d1_8k.htm   iXBRL 8-K 29611
  Complete submission text file 0001104659-25-068670.txt   237756

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA limn-20250716.xsd EX-101.SCH 3359
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE limn-20250716_def.xml EX-101.DEF 26585
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE limn-20250716_lab.xml EX-101.LAB 36487
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE limn-20250716_pre.xml EX-101.PRE 25209
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2521089d1_8k_htm.xml XML 5328
Mailing Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623
Business Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623 213-273-5453
Liminatus Pharma, Inc. (Filer) CIK: 0001971387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42626 | Film No.: 251130860
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)